These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 31585170)

  • 1. Can BDDCS illuminate targets in drug design?
    Bocci G; Benet LZ; Oprea TI
    Drug Discov Today; 2019 Dec; 24(12):2299-2306. PubMed ID: 31585170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Disposition Classification Systems in Discovery and Development: A Comparative Review of the BDDCS, ECCS and ECCCS Concepts.
    Camenisch GP
    Pharm Res; 2016 Nov; 33(11):2583-93. PubMed ID: 27439505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BDDCS Predictions, Self-Correcting Aspects of BDDCS Assignments, BDDCS Assignment Corrections, and Classification for more than 175 Additional Drugs.
    Hosey CM; Chan R; Benet LZ
    AAPS J; 2016 Jan; 18(1):251-60. PubMed ID: 26589308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BDDCS applied to over 900 drugs.
    Benet LZ; Broccatelli F; Oprea TI
    AAPS J; 2011 Dec; 13(4):519-47. PubMed ID: 21818695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of Biopharmaceutical Drug Disposition Classification System (BDDCS) by Structural Parameters.
    Golfar Y; Shayanfar A
    J Pharm Pharm Sci; 2019; 22(1):247-269. PubMed ID: 31287788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development.
    Benet LZ
    J Pharm Sci; 2013 Jan; 102(1):34-42. PubMed ID: 23147500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BDDCS class prediction for new molecular entities.
    Broccatelli F; Cruciani G; Benet LZ; Oprea TI
    Mol Pharm; 2012 Mar; 9(3):570-80. PubMed ID: 22224483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative analysis of biopharmaceutics classification system and biopharmaceutics drug disposition classification system: a cross-sectional survey with 500 bioequivalence studies.
    Cristofoletti R; Chiann C; Dressman JB; Storpirtis S
    J Pharm Sci; 2013 Sep; 102(9):3136-44. PubMed ID: 23580377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery.
    Varma MV; Gardner I; Steyn SJ; Nkansah P; Rotter CJ; Whitney-Pickett C; Zhang H; Di L; Cram M; Fenner KS; El-Kattan AF
    Mol Pharm; 2012 May; 9(5):1199-212. PubMed ID: 22489626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Few Drugs Display Flip-Flop Pharmacokinetics and These Are Primarily Associated with Classes 3 and 4 of the BDDCS.
    Garrison KL; Sahin S; Benet LZ
    J Pharm Sci; 2015 Sep; 104(9):3229-35. PubMed ID: 26010239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. State of the Art and Uses for the Biopharmaceutics Drug Disposition Classification System (BDDCS): New Additions, Revisions, and Citation References.
    Bocci G; Oprea TI; Benet LZ
    AAPS J; 2022 Feb; 24(2):37. PubMed ID: 35199251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system.
    Wu CY; Benet LZ
    Pharm Res; 2005 Jan; 22(1):11-23. PubMed ID: 15771225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Biopharmaceutics Classification System (BCS) and the Biopharmaceutics Drug Disposition Classification System (BDDCS): Beyond guidelines.
    Charalabidis A; Sfouni M; Bergström C; Macheras P
    Int J Pharm; 2019 Jul; 566():264-281. PubMed ID: 31108154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting Interactions between Rifampin and Antihypertensive Drugs Using the Biopharmaceutics Drug Disposition Classification System.
    Liu W; Yan T; Chen K; Yang L; Benet LZ; Zhai S
    Pharmacotherapy; 2020 Apr; 40(4):274-290. PubMed ID: 32100890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies.
    Bauer RA
    Drug Discov Today; 2015 Sep; 20(9):1061-73. PubMed ID: 26002380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The biopharmaceutics risk assessment roadmap for optimizing clinical drug product performance.
    Selen A; Dickinson PA; Müllertz A; Crison JR; Mistry HB; Cruañes MT; Martinez MN; Lennernäs H; Wigal TL; Swinney DC; Polli JE; Serajuddin ATM; Cook JA; Dressman JB
    J Pharm Sci; 2014 Nov; 103(11):3377-3397. PubMed ID: 25256402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neural Network Models for Predicting Solubility and Metabolism Class of Drugs in the Biopharmaceutics Drug Disposition Classification System (BDDCS).
    Ashrafi A; Teimouri K; Aghazadeh F; Shayanfar A
    Eur J Drug Metab Pharmacokinet; 2024 Jan; 49(1):1-6. PubMed ID: 37864650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo rat PK profiling in drug discovery: new challenges.
    Zonzini L; Bianchi F; Cesari N; Sartori M
    Expert Opin Drug Discov; 2010 Nov; 5(11):1031-7. PubMed ID: 22827743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A modern in vivo pharmacokinetic paradigm: combining snapshot, rapid and full PK approaches to optimize and expedite early drug discovery.
    Li C; Liu B; Chang J; Groessl T; Zimmerman M; He YQ; Isbell J; Tuntland T
    Drug Discov Today; 2013 Jan; 18(1-2):71-8. PubMed ID: 22982770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BDDCS, the Rule of 5 and drugability.
    Benet LZ; Hosey CM; Ursu O; Oprea TI
    Adv Drug Deliv Rev; 2016 Jun; 101():89-98. PubMed ID: 27182629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.